Tiziana Life Sciences Initiates Phase 2 Alzheimer’s Trial with Innovative Approach
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Tiziana Life Sciences ( (TLSA) ).
On December 12, 2025, Tiziana Life Sciences announced the commencement of enrollment for its Phase 2 clinical trial targeting early Alzheimer’s disease. The trial will assess the efficacy of intranasal foralumab, both as a standalone treatment and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab. This trial is significant as it explores a novel approach to treating Alzheimer’s by addressing neuroinflammation, which persists even after amyloid plaque reduction. The study’s outcomes could potentially redefine treatment paradigms for Alzheimer’s by focusing on immune modulation.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company specializes in immunotherapy, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Tiziana aims to improve the efficacy, safety, and tolerability of treatments compared to traditional intravenous delivery methods.
Average Trading Volume: 316,962
Technical Sentiment Signal: Buy
Current Market Cap: $200.6M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.
